You are here
Peninsula Health Technology Commissioning Group Commissioning decision: dasatinib and nilotinib in the management of CML
The Peninsula Health Technology Commissioning Group (PHTCG) has come to a decision on the use of dasatinib and nilotinib in the management of chronic myeloid leukaemia.
Where clinically appropriate these drugs may be used for patients who are resistant to standard first line therapy with imatinib who are in either the chronic or accelerated phase of the disease.
They may also be used for patients in these phases who cannot tolerate imatinib.
Full text here:
www.devonpct.nhs.uk